| activation of the RhoA-ROCK-p38MAPK-MSK signaling pathway is essential for the regulation of the phenotype and of the CST5/cystatin D candidate tumor suppressor and other target genes by 1,25(OH)2D3 in colon cancer cells | colorectal, |
| These results suggested that the tumour suppressor homologue SRO7/SRO77 regulated cell proliferation and yeast colony development via the Rho1-Tor1 pathway. | colorectal, |
| p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. | None |
| RhoA, a novel tumor suppressor or oncogene as a therapeutic target? | None |
| RhoA signaling pathways are able to regulate transcription in cortical neurons by triggering translocation of serum response factor co-activator megakaryoblastic leukemia oncogene protein MAL. | leukemia, |
| RHOA, and its oncogenic signaling pathway, represent a strong biomarker-driven therapeutic target for Asian gastric cancer. | gastric, |
| STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. | None |
| oncogenic Skp2 and Myc coordinate to induce RhoA transcription and establish a novel SCF-Skp2 E3-ligase-independent function for oncogenic Skp2 in transcription and cancer metastasis. | None |
| Induction of human microsomal prostaglandin E synthase 1 by activated oncogene RhoA GTPase in A549 human epithelial cancer cells. | None |
| our results suggest a role for oncogenic RHOA mutation in the development of gastrointestinal cancers. | None |